---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-096985"
form_type: "8-K"
ticker: "KOD"
cik: "0001468748"
company_name: "Kodiak Sciences Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:17:54.557399+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kodiak Sciences Q2 net loss $45.1M, cash $219.2M; three Phase trials enrolling

## Summary
- Net loss $45.1M ($0.86/sh) vs $80.2M ($1.53/sh) in Q2 2023; R&D expense down 52% to $32.5M.
- Cash and cash equivalents $219.2M; company believes funds operations into 2026.
- Phase 3 GLOW2 (diabetic retinopathy) and DAYBREAK (wet AMD) actively enrolling; Phase 1b APEX (KSI-101) enrolling.
- Appointed Dolly Chang (ex-Genentech) as CSO; promoted Almas Qudrat (CQO), Wayne To (CTO), Pablo Velazquez-Martin (CMO).
- Investor Day scheduled for September 23, 2024.

## SEC filing metadata
- accession: 0000950170-24-096985
- form_type: 8-K
- ticker: KOD
- cik: 0001468748
- company_name: Kodiak Sciences Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468748/000095017024096985/0000950170-24-096985-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468748/000095017024096985/kod-20240814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-096985
- JSON: https://secwatch.observer/filing/0000950170-24-096985.json
- Plain text: https://secwatch.observer/filing/0000950170-24-096985.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.